Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD19

CD19

Brief Information

Name:B-lymphocyte antigen CD19
Target Synonym:Differentiation antigen CD19,CD19 Molecule,B-Lymphocyte Surface Antigen B4,CD19 Antigen,B-Lymphocyte Antigen CD19,CVID3,B4,Antigens, CD19,CD19,T-cell surface antigen Leu-12
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:181
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BIA202202 Autoimmune diseases/ B cell malignancies Apply for IND License-out or co-development

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD9-HA2H9 Human APC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H9-structure
CD9-HP2H5 Human PE-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HP2H5-structure
CD9-R52H6 Rat Rat CD19 Protein, His Tag
CD9-R52H6-structure
CD9-R52H6-sds
CD9-C52H4 Canine Canine CD19 Protein, His Tag
CD9-C52H4-structure
CD9-C52H4-sds
CD9-R52H3 Rabbit Rabbit CD19 Protein, His Tag
CD9-R52H3-structure
CD9-R52H3-sds
CD9-HF2H3 Human FITC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HF2H3-structure
CD9-HF2H3-sds
CD9-C5221 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, His Tag
CD9-C5221-structure
CD9-C5221-sds
MBS-K005 Human Human CD19-coupled Magnetic Beads
MBS-K005-elisa_1
CD9-H82E9 Human Biotinylated Human CD19 (20-291) Protein, His,Avitag™ (SPR verified) DMF Filed
CD9-H82E9-structure
CD9-H82E9-sds
CD9-H82E9-elisa_1
CD9-H82E9-elisa_2
CD9-HP2H3 Human PE-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation) DMF Filed
CD9-HP2H3-structure
CD9-H82F7 Human Biotinylated Human CD19 (20-291) Protein, Fc,Avitag™
CD9-H82F7-structure
CD9-H82F7-sds
CD9-H82F7-elisa_1
CD9-H82F7-elisa_2
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag
CD9-H5258-structure
CD9-H5258-sds
CD9-H5258-elisa_1
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag DMF Filed
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity, MALS verified) DMF Filed
CD9-H5251-structure
CD9-H5251-sds
CD9-H5251-elisa_1
CD9-H5251-elisa_2
CD9-H5250 Human Human CD19 (20-291) Protein, Llama IgG2b Fc Tag, low endotoxin
CD9-H5250-structure
CD9-H5250-sds
CD9-H5250-elisa_1
CD9-H5250-elisa_2
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-H52H2-structure
CD9-H52H2-sds
CD9-H52H2-elisa_1
CD9-H52H2-elisa_2
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H8259 Human Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling) DMF Filed
CD9-H8259-structure
CD9-H8259-sds
CD9-H8259-elisa_1
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds
CD9-H5259-elisa_1
CD9-H5259-elisa_2

Part of Bioactivity data

CD9-HP2H5-Cell-based assay
Evaluation of CAR expression

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H5) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

CD9-H82E9-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested).

CD9-H82F7-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CD19 (20-291), Fc,Avitag (Cat. No. CD9-H82F7) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.177 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CD19,B4,CVID3,MGC12802

Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brexucabtagene autoleucel KTE-X19 Approved Kite Pharma Inc, Gilead Sciences Inc Tecartus EU Lymphoma, Mantle-Cell Kite Pharma Eu Bv 2020-07-24 Lymphoma, Mantle-Cell Details
Lisocabtagene maraleucel (Celgene/Juno Therapeutics) JCAR-017; Liso-Cel Approved Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center, Juno Therapeutics Breyanzi Japan Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse Celgene Corp 2021-02-05 Lymphoma, B-Cell; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma Details
Tafasitamab XmAb-5574; MOR-208; XENP-5574; MOR-00208 Approved Xencor MONJUVI EU Lymphoma, Large B-Cell, Diffuse Incyte Biosciences Distribution Bv 2020-07-31 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Tisagenlecleucel LG-740; CART-19; CTL-019; CART-019 Approved University Of Pennsylvania, Novartis Pharma Ag Kymriah EU Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse Novartis Europharm Ltd 2017-08-30 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
Relmacabtagene autoleucel JWCAR-029 Approved Suzhou Yaomingjunuo Biotechnology Co Ltd 倍诺达, Carteyva Mainland China Lymphoma, Large B-Cell, Diffuse Jw Therapeutics (Shanghai) Co Ltd 2021-09-01 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Loncastuximab tesirine ADCT-402 Approved Adc Therapeutics Lonca, ZYNLONTA United States Lymphoma, Large B-Cell, Diffuse Adc Therapeutics Sa 2021-04-23 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Blinatumomab MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 Approved Amgen Inc 倍利妥, Blincyto Mainland China Precursor Cell Lymphoblastic Leukemia-Lymphoma Amgen Inc 2014-12-03 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Axicabtagene ciloleucel KTE-C19; KTE C19; FKC-876 Approved Cabaret Biotech, Gilead Sciences Inc Yescarta, 奕凯达 Mainland China Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, B-Cell Fosun Kite Biotechnology Co Ltd 2017-10-18 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Inebilizumab 16C4-aFuc; MEDI-551; MT-0551; VIB-0551 Approved Duke University, Horizon Therapeutics Plc Uplinza, ユプリズナ, Uplizna Japan Neuromyelitis Optica Mitsubishi Tanabe Pharma 2020-06-11 Myasthenia Gravis; Hematologic Neoplasms; Lymphoma, B-Cell; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
4G7SDIE Clinical Synimmune, The University Of Tubingen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) Phase 1 Clinical University Hospitals Cleveland Medical Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
TC-110 TC-110 Phase 2 Clinical Tcr2 Therapeutics Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
aCD19z aCD19z Phase 1 Clinical Christie Hospital Nhs Foundation Trust Lymphoma, Non-Hodgkin Details
PTG-01 PTG-01 Phase 1 Clinical Protheragen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-20-19-22(Medical College of Wisconsin) CAR-20-19-22 The Medical College Of Wisconsin Nonprofit Details
PCAR-119 (PersonGen Biomedicine) PCAR-119 Phase 2 Clinical Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
ThisCART-19 ThisCART-19 Phase 1 Clinical Lymphoma, B-Cell Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell Details
H-31970-SAGAN H-31970-SAGAN Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Phase 3 Clinical Chaim Sheba Medical Center At Tel Hashomer Leukemia, Myeloid, Acute Details
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-19 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) Phase 1 Clinical Xinqiao Hospital, Army Medical University Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
GC-022 GC-022; GC-022F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Leukemia, Lymphoid Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Details
Anti-BCMA/CD19 CAR-T(Autolus) Phase 1 Clinical Multiple Myeloma Details
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) Clinical Leidos Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CAR CD19-CAR Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia; Lymphoma Details
Anti-CD19 CAR T-cell therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Coltuximab ravtansine SAR-3419; huB4-DM4 Phase 2 Clinical Immunogen Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) Phase 1 Clinical Hebei Yanda Hospital Lymphoma, B-Cell Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
Virus-specific-CD19.CAR Phase 1 Clinical Baylor College Of Medicine Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD Phase 1 Clinical University College London Lymphoma Details
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
CD19.CAR-VST CD19.CAR-VST Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) Phase 1 Clinical Kecellitics Biotech Company Ltd Leukemia; Lymphoma Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Bioceltech) Clinical Bioceltech Therapeutics Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PCAR-019 (Anke Biotechnology) Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19 CAR-T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) Phase 2 Clinical Wuhan Bio-Raid Biotechnology Hematologic Diseases; Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Uppsala University) Phase 2 Clinical Uppsala University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore) Phase 1 Clinical National University Health System Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) SENL-B19 Phase 2 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia; Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma Details
HuCART19 Phase 2 Clinical National Cancer Institute, Kite Pharma Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) Phase 2 Clinical Xuanwu Hospital Of Capital Medical University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase 1 Clinical Nagoya University, Shinshu University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) Phase 2 Clinical Suzhou University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) Phase 2 Clinical Bioray Laboraytories Inc Leukemia Details
CAR-CD19 T cell therapy Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Clinical Pinze Lifetechnology Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
CLIC-1901 (Ottawa Hospital Research Institute) CLIC-1901 Phase 2 Clinical Ottawa Hospital Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
AMG-562 AMG-562 Phase 1 Clinical Amgen Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) Phase 1 Clinical Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) Phase 2 Clinical Shanghai Zhongshan Hospital, Hrain Biotechnology Candidiasis, Vulvovaginal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) yinnuokati-19 Phase 2 Clinical Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) XLCART-001 Phase 2 Clinical Nanjing Medical University Lymphoma, B-Cell Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase 2 Clinical Bluebird Bio Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19.CAR T Cells (University Hospital Heidelberg) Phase 2 Clinical University Of Heidelberg Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.) Phase 1 Clinical Hebei Yanda Hospital, China Immunotech Co Ltd Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) BPX-401 Phase 2 Clinical Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) WZTL002-1 Phase 1 Clinical The Malaghan Institute Of Medical Research Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
4-1BBz CD19-Her2tG (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Neoplasms Details
PBLTT52CAR19 Phase 1 Clinical Great Ormond Street Hospital For Children Nhs Foundation Trust Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, Non-Hodgkin Details
CTA-30X CTA30X; CTA-30X Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET190; ET-190; ET190L1; ET190L1-ARTEMI Phase 1 Clinical Eureka Therapeutics Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) Clinical Nanjing Kati Medical Technology Co Ltd Neoplasms Details
TI-1007 TI-1007 Phase 2 Clinical Tianjin Timmune Biotech Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
MC-19PD1 CAR-T cell therapy (Peking University) Phase 1 Clinical Peking University Lymphoma, B-Cell Details
CD19 CARvac T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, B-Cell; Leukemia, B-Cell Details
BZ019 BZ-019 Phase 1 Clinical Shanghai Cell Therapy Research Institute Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) Phase 1 Clinical China Immunotech Co Ltd Lymphoma, Non-Hodgkin Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) CARCIK-CD19; CIK-CAR.CD19 Phase 2 Clinical Fondazione Matilde Tettamanti Menotti De Marchi Onlus Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase 1 Clinical Juno Therapeutics Hematologic Neoplasms Details
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital) Phase 2 Clinical Beijing Boren Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PACE CART-19 cell therapy (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD22 bispecific CAR-T (Zhejiang University) Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Clinical Hebei Senlang Biological Technology Co Ltd Leukemia Details
TAC01-CD19 TAC01-CD19 Phase 2 Clinical Triumvira Immunologics Lymphoma, B-Cell Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Neoplasms Details
U-CART (Shanghai Bioray Laboratory Inc) Phase 2 Clinical Bioray Laboraytories Inc Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-19 S-68587; UCART-19 Phase 1 Clinical Cellectis Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 2 Clinical The First Affiliated Hospital Of Nanchang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) Phase 1 Clinical Aikangd Biomedical Technology (Suzhou) Co Ltd Leukemia; Lymphoma Details
ET-019002 ET-019002 Phase 1 Clinical Eureka Therapeutics Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase 2 Clinical Sinobioway Biomedicine Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma Details
CC-97540 CC-97540 Phase 1 Clinical Juno Therapeutics Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma Details
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) Phase 1 Clinical Tianjin Timmune Biotech Inc Leukemia; Lymphoma, Non-Hodgkin Details
Humanized CD19 CAR-T cell therapy (Yake) YK-C19 Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid Details
Murine CD19 CAR-T cell therapy (Yake) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) Phase 1 Clinical Beijing Yongtai Rec Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
RO-7227166 RO-7227166 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
ICT19G1 ICT-19G1 Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CD19 CAR-T cell therapy (National University of Malaysia) Phase 3 Clinical National University Of Malaysia Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) Phase 1 Clinical China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital Lymphoma, B-Cell Details
TG-1801 NI-1701; TG-1801 Phase 1 Clinical Novimmune Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
GTB-1550 DT-2219; OXS-1550; DT-2219ARL; IND-100780 Phase 2 Clinical University Of Minnesota Leukemia; Lymphoma, B-Cell Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CTL-119 CTL-119 Phase 2 Clinical University Of Pennsylvania, Novartis Pharma Ag Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) Phase 1 Clinical Memorial Sloan Kettering Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CART-19 cells (Henan Hualong Biotechnology) Phase 2 Clinical Henan Hualong Biotechnology Leukemia, Lymphoid Details
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells TAK-940 Phase 1 Clinical Takeda Neoplasms Details
Senl-1904A Senl-1904A; Senl_1904A Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-T 19 cell therapy (University of Pennsylvania) Phase 2 Clinical University Of Pennsylvania Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) Phase 1 Clinical Lymphoma, Non-Hodgkin Details
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) Phase 1 Clinical Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Lymphoma, B-Cell; Leukemia, Lymphoid; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) Phase 1 Clinical Institute Of Hematology & Blood Diseases Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital Leukemia Details
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology) Phase 1 Clinical Wuhan Si'an Medical Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
AUTO-3 AUTO-3 Phase 2 Clinical University College London Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
RPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell) Phase 1 Clinical Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
FT-819 FT-8198; FT-819 Phase 1 Clinical Fate Therapeutics Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion, Czech Republic) Institute of Hematology and Blood Transfusion, Czech Republic Details
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) Phase 2 Clinical University Of Alberta Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) Phase 1 Clinical Kunming Medical University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CART Phase 2 Clinical Hrain Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19 CAR engineered autologous T-cells(Sabz Biomedicals) Phase 1 Clinical Leukemia, Biphenotypic, Acute Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Chengdu Yinhe Biomedicine Co Ltd, Beijing Mali Biotechnology Co Ltd Lymphoma, B-Cell Details
JCAR-014 JCAR-014 Phase 2 Clinical Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Takara Bio Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
JCAR-015 JCAR-15; JCAR-015; 19-28z-T-Cells; 19-28z+ T cells; 19-28z CAR T cells Phase 2 Clinical Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
GC-012F GC-012F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Multiple Myeloma Details
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy GC-197 Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
GC-007F (Gracell Biotechnology) GC-007F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Lymphoma, B-Cell Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 1 Clinical The First Affiliated Hospital Of Nanchang University Multiple Myeloma Details
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology POEMS Syndrome Details
CD19-directed T-cell immunotherapy (CRISPR Therapeutics) CTX-110 Phase 1 Clinical Crispr Therapeutics Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
GC019F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Juventas) CNCT19; CNCT-19; HY001 Phase 2 Clinical Heyuan Biotechnology (Tianjin) Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Allogeneic CD-19 CAR-T Cell Therapy Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
ALLO-501 ALLO-501 Phase 2 Clinical Cellectis Lymphoma, B-Cell; Lymphoma, Follicular Details
Bispecific CD19/22 CAR T cells Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
ALLO-501A ALLO-501A Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell Details
UCART019 UCART-019 Phase 2 Clinical The General Hospital Of The People'S Liberation Army Lymphoma, B-Cell; Leukemia, B-Cell Details
TanCART19/20 Phase 1 Clinical The General Hospital Of The People'S Liberation Army Neuromyelitis Optica Details
19273-4SCAR 19273-4SCAR Phase 2 Clinical Peking University Lymphoma, B-Cell Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
4SCAR19/22 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19/CD22 targeted CAR-T cells Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
BinD-19 (Shenzhen BinDeBio) BinD-19 Phase 2 Clinical Shenzhen Bindebio Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
NCAR19-T Phase 2 Clinical Second Military Medical University Of Chinese People'S Liberation Army Lymphoma, B-Cell Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase 2 Clinical Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University Lymphoma, B-Cell; Leukemia, B-Cell Details
C-CAR039 EXP-039; C-CAR039; C-CAR-039 Phase 1 Clinical Cellular Biomedicine Group Ltd Lymphoma, Non-Hodgkin Details
GB5005 chimeric antigen receptor T cell therapy (Genbase) Phase 1 Clinical Shanghai Genbase Biotechnology Co Ltd Leukemia, B-Cell Details
CD19 CAR-T (HuaDao CAR-Tcell) Phase 1 Clinical Huadao (Shanghai) Biopharma Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
TAK-007 TAK-007 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Obecabtagene autoleucel AUTO-1; AUTO1; Obe-cel Phase 2 Clinical University College London Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
NKX-019 NKX-019 Phase 1 Clinical Nkarta Inc Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
IMJ-995 IMJ-995 Phase 1 Clinical Novartis Pharma Ag Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh Immunologic Deficiency Syndromes Details
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
A-319(Evive Biotech) A-319 Phase 1 Clinical Evive Biotech Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Duvortuxizumab MGD-011; JNJ-64052781 Phase 1 Clinical Macrogenics Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
K-193 K-193 Phase 1 Clinical Beijing Lvzhu Biological Technology Co Ltd Lymphoma, B-Cell Details
CN-201 CN-201 Phase 1 Clinical Tongrun Biomedicine (Shanghai) Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
AFM-11 AFM-11 Phase 1 Clinical Affimed Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
GNR-084 GNR-084 Phase 2 Clinical Generium Pharmaceuticals, Iontas Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
RGV-004 RGV-004 Phase 1 Clinical Hangzhou Rongu Biotechnology Co Ltd Lymphoma, B-Cell Details
CRC-01 Phase 2 Clinical Curocell Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Details
1-A-46 1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 Phase 1 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd Lymphoma, Non-Hodgkin Details
GC007g GC-007G Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
CLBR-001/SWI-019 CLBR-001/SWI-019 Phase 1 Clinical Abbvie Inc, California Institute For Biomedical Research Lymphoma, B-Cell Details
GNC-038 GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
PBCAR-0191 PBCAR-0191 Phase 2 Clinical Baxalta Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) Phase 2 Clinical Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
CD19-CART (Unicar-Therapy Bio-medicine Technology) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 UCAR-T cell Therapy Phase 1 Clinical Gracell Biotechnology Ltd Lymphoma, B-Cell; Leukemia, Biphenotypic, Acute Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) ssCART-19 Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
YTB-323 YTB-323 Phase 2 Clinical Novartis Pharma Ag Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
pCAR-19B Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
SNUH-CD19-CAR-T SNUH-CD19-CAR-T Seoul National University Hospital Details
IM19CAR-T Phase 2 Clinical Beijing Yimiao Medical Technology Co Ltd Leukemia; Hematologic Neoplasms; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin Details
XYF19 CAR-T cell therapy (Xijing Hospital) Phase 1 Clinical Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-human CD19-CD22 T cell therapy Phase 1 Clinical Hrain Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
KUR-502 CD19 CAR-NKT KUR-502; CMD-502 Phase 1 Clinical Athenex Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) Zhejiang University Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message